WO2009102962A3 - Combination of alpha 7 nicotinic agonists and antipsychotics - Google Patents

Combination of alpha 7 nicotinic agonists and antipsychotics Download PDF

Info

Publication number
WO2009102962A3
WO2009102962A3 PCT/US2009/034062 US2009034062W WO2009102962A3 WO 2009102962 A3 WO2009102962 A3 WO 2009102962A3 US 2009034062 W US2009034062 W US 2009034062W WO 2009102962 A3 WO2009102962 A3 WO 2009102962A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination
antipsychotics
alpha
nicotinic agonists
nicotinic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/034062
Other languages
French (fr)
Other versions
WO2009102962A2 (en
Inventor
Merouane Bencherif
Gregory J. Gatto
Terry Hauser
Kristen G. Jordan
Sharon R. Letchworth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gyre Therapeutics Inc
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2010008875A priority Critical patent/MX2010008875A/en
Priority to AU2009214625A priority patent/AU2009214625A1/en
Priority to HK11102160.7A priority patent/HK1147954B/en
Priority to JP2010546920A priority patent/JP2011511845A/en
Priority to SI200930714T priority patent/SI2254598T1/en
Priority to HRP20130749AT priority patent/HRP20130749T1/en
Priority to CA2715268A priority patent/CA2715268A1/en
Priority to DK09709577.2T priority patent/DK2254598T3/en
Priority to ES09709577T priority patent/ES2430622T3/en
Priority to CN2009801102033A priority patent/CN101977628A/en
Priority to US12/867,073 priority patent/US20110059947A1/en
Priority to PL09709577T priority patent/PL2254598T3/en
Priority to EP09709577.2A priority patent/EP2254598B1/en
Priority to RU2010137787/15A priority patent/RU2481123C2/en
Priority to RS20130387A priority patent/RS52941B/en
Priority to BRPI0907570A priority patent/BRPI0907570A2/en
Application filed by Targacept Inc filed Critical Targacept Inc
Priority to NZ587312A priority patent/NZ587312A/en
Publication of WO2009102962A2 publication Critical patent/WO2009102962A2/en
Publication of WO2009102962A3 publication Critical patent/WO2009102962A3/en
Priority to IL207389A priority patent/IL207389A0/en
Anticipated expiration legal-status Critical
Priority to ZA2010/05999A priority patent/ZA201005999B/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

The present invention relates to a synergistic combination of an alpha7 (α7) nicotinic agonist and an antipsychotic agent.
PCT/US2009/034062 2008-02-13 2009-02-13 Combination of alpha 7 nicotinic agonists and antipsychotics Ceased WO2009102962A2 (en)

Priority Applications (19)

Application Number Priority Date Filing Date Title
US12/867,073 US20110059947A1 (en) 2008-02-13 2009-02-13 Alpha 7 nicotinic agonists and antipsychotics
HK11102160.7A HK1147954B (en) 2008-02-13 2009-02-13 Combination of alpha 7 nicotinic agonists and antipsychotics
JP2010546920A JP2011511845A (en) 2008-02-13 2009-02-13 Combination of alpha 7 (α7) nicotinic agonist and antipsychotic
SI200930714T SI2254598T1 (en) 2008-02-13 2009-02-13 Combination of alpha 7 nicotinic agonists and antipsychotics
HRP20130749AT HRP20130749T1 (en) 2008-02-13 2009-02-13 Combination of alpha 7 nicotinic agonists and antipsychotics
AU2009214625A AU2009214625A1 (en) 2008-02-13 2009-02-13 Combination of alpha 7 nicotinic agonists and antipsychotics
DK09709577.2T DK2254598T3 (en) 2008-02-13 2009-02-13 COMBINATION OF ALFA 7-NICOTINAGONISTS AND ANTI-CYCOTICS
ES09709577T ES2430622T3 (en) 2008-02-13 2009-02-13 Combination of alpha 7 nicotinic and antipsychotic agonists
CN2009801102033A CN101977628A (en) 2008-02-13 2009-02-13 Combinations of alpha 7 nicotinic agonists and antipsychotics
PL09709577T PL2254598T3 (en) 2008-02-13 2009-02-13 Combination of alpha 7 nicotinic agonists and antipsychotics
CA2715268A CA2715268A1 (en) 2008-02-13 2009-02-13 Alpha 7 nicotinic agonists and antipsychotics
MX2010008875A MX2010008875A (en) 2008-02-13 2009-02-13 Combination of alpha 7 nicotinic agonists and antipsychotics.
RU2010137787/15A RU2481123C2 (en) 2008-02-13 2009-02-13 Combination of alpha 7 nicotinic receptor agonists and antipsychotic agents
RS20130387A RS52941B (en) 2008-02-13 2009-02-13 A COMBINATION OF ALFA 7 NICOTINE AGONISTS AND ANTIPSYCHOTICS
BRPI0907570A BRPI0907570A2 (en) 2008-02-13 2009-02-13 alpha7 nicotinic agonists and antipsychotics
EP09709577.2A EP2254598B1 (en) 2008-02-13 2009-02-13 Combination of alpha 7 nicotinic agonists and antipsychotics
NZ587312A NZ587312A (en) 2008-02-13 2009-02-13 Combination of alpha 7 nicotinic agonists and antipsychotics
IL207389A IL207389A0 (en) 2008-02-13 2010-08-03 Alpha 7 nicotinic agonists and antipsychotics
ZA2010/05999A ZA201005999B (en) 2008-02-13 2010-08-23 Combination of alpha 7 nicotinic agonists and antipsychotics

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2828208P 2008-02-13 2008-02-13
US61/028,282 2008-02-13

Publications (2)

Publication Number Publication Date
WO2009102962A2 WO2009102962A2 (en) 2009-08-20
WO2009102962A3 true WO2009102962A3 (en) 2009-10-08

Family

ID=40902222

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/034062 Ceased WO2009102962A2 (en) 2008-02-13 2009-02-13 Combination of alpha 7 nicotinic agonists and antipsychotics

Country Status (25)

Country Link
US (1) US20110059947A1 (en)
EP (2) EP2254598B1 (en)
JP (1) JP2011511845A (en)
KR (1) KR20100113163A (en)
CN (2) CN101977628A (en)
AU (1) AU2009214625A1 (en)
BR (1) BRPI0907570A2 (en)
CA (1) CA2715268A1 (en)
CO (1) CO6290706A2 (en)
CY (1) CY1114492T1 (en)
DK (1) DK2254598T3 (en)
EC (1) ECSP10010471A (en)
ES (1) ES2430622T3 (en)
HR (1) HRP20130749T1 (en)
IL (1) IL207389A0 (en)
MX (1) MX2010008875A (en)
NZ (1) NZ587312A (en)
PL (1) PL2254598T3 (en)
PT (1) PT2254598E (en)
RS (1) RS52941B (en)
RU (1) RU2481123C2 (en)
SG (1) SG188144A1 (en)
SI (1) SI2254598T1 (en)
WO (1) WO2009102962A2 (en)
ZA (1) ZA201005999B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464078B2 (en) 2010-09-23 2016-10-11 Abbvie Inc. Monohydrate of azaadamantane derivatives

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
SA08290475B1 (en) * 2007-08-02 2013-06-22 Targacept Inc (2S,3R)-N-(2-((3-pyrdinyl)methyl)-1-aza bicyclo[2,2,2]oct-3-yl)benzofuran-2-carboxamide, its new salt forms and methods of use
EP2665478A1 (en) * 2011-01-18 2013-11-27 Targacept, Inc. Treatment of cognitive dysfunction in schizophrenia
US9139576B2 (en) 2011-05-03 2015-09-22 Merck Sharp & Dohme Corp. Aminomethyl biaryl benzotriazole derivatives
MX2015004285A (en) * 2012-10-02 2015-08-06 Sumitomo Dainippon Pharma Co Ltd Imidazole derivative.
JP6807094B2 (en) * 2016-04-29 2021-01-06 国立大学法人秋田大学 Method for determining risk of increased blood drug concentration and method for determining drug dose of clozapine or its derivative
CN110087641B (en) 2016-12-20 2024-03-12 罗曼治疗系统股份公司 Transdermal therapeutic systems containing asenapine and polysiloxane or polyisobutylene
PL3338768T3 (en) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN108727416B (en) * 2017-04-20 2021-03-09 北京大学 Tricyclic heteroaromatic amide derivative and preparation and application thereof
JP2020525545A (en) 2017-06-26 2020-08-27 エルテーエス ローマン テラピー−ジステーメ アーゲー Transdermal therapeutic system containing asenapine and silicone-acrylic hybrid polymer
CN107469087A (en) * 2017-09-10 2017-12-15 孙永丽 For antipsychotic preparation
CN118806732A (en) 2018-06-20 2024-10-22 罗曼治疗系统股份公司 Transdermal therapeutic system containing asenapine
BR112020026099A2 (en) 2018-06-20 2021-03-23 Lts Lohmann Therapie-Systeme Ag transdermal therapeutic system containing asenapine
WO2022150560A1 (en) * 2021-01-08 2022-07-14 Ifm Due, Inc. Compounds and compositions for treating conditions associated with sting activity
JP2024502474A (en) 2021-01-08 2024-01-19 アイエフエム デュー インコーポレイテッド Urea-bearing heterobicyclic compounds or analogs and compositions thereof for treating conditions associated with STING activity
DE102022114269A1 (en) 2022-06-07 2023-12-07 Rational Aktiengesellschaft Cooking device with a self-cleaning system and a method for changing cleaning parameters for the cooking device

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070731A2 (en) * 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
WO2004052894A1 (en) * 2002-12-06 2004-06-24 Pharmacia & Upjohn Company Llc Crystalline fumarate salts of 1-azabicyclo[2.2.2]oct substituted furo[2,3-c]pyridinyl carboxamide and compositions and preparations thereof
WO2004099202A1 (en) * 2003-05-05 2004-11-18 Pharmacia & Upjohn Company Llc Quinuclidines substituted bentodioxine carboxamides for the treatment of neurodegenerative diseases
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
US7309699B2 (en) * 2003-12-22 2007-12-18 Abbott Laboratories 3-Quinuclidinyl amino-substituted biaryl derivatives

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597919A (en) * 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5712270A (en) 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
SE9600683D0 (en) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
US5663356A (en) * 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
AR013184A1 (en) 1997-07-18 2000-12-13 Astrazeneca Ab SPYROZOBICYCLIC HETERO CYCLIC AMINES, PHARMACEUTICAL COMPOSITION, USE OF SUCH AMINES TO PREPARE MEDICINES AND METHOD OF TREATMENT OR PROPHYLAXIS
AU765142B2 (en) 1998-06-01 2003-09-11 Ortho-Mcneil Pharmaceutical, Inc. Method for treating neurodegenerative disorders
SE9904176D0 (en) 1999-11-18 1999-11-18 Astra Ab New use
BR0016168A (en) * 1999-12-10 2002-08-20 Therapeutic combinations of (s) -2- (benzylaminomethyl) -2,3,8,9tetrahydro-7h-1,4-dioxy in [2,3 -e] indol-8-one and neuroleptics for the treatment or prevention of disorders psychotic
AU2001266100B9 (en) * 2000-06-27 2005-10-06 Laboratorios S.A.L.V.A.T., S.A. Carbamates derived from arylalkylamines
US6486172B2 (en) 2000-08-18 2002-11-26 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6492386B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
AU2001282874A1 (en) 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
WO2002017358A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
WO2002015662A2 (en) 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
JP2004506734A (en) 2000-08-21 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー Quinuclide-substituted heteroaryl moieties for disease treatment
US6554086B1 (en) * 2000-10-27 2003-04-29 Invacare Corporation Obstacle traversing wheelchair
EP1345937B1 (en) 2000-12-22 2005-09-28 Almirall Prodesfarma AG Quinuclidine carbamate derivatives and their use as m3 antagonists
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
EP1699488A2 (en) * 2003-12-23 2006-09-13 Pfizer Products Incorporated Therapeutic combination for cognition enhancement and psychotic disorders
EP1863485A2 (en) * 2005-03-18 2007-12-12 Abbott Laboratories Alpha7 neuronal nicotinic receptor ligand and antipsychotic compositions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6953855B2 (en) * 1998-12-11 2005-10-11 Targacept, Inc. 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof
WO2003070731A2 (en) * 2002-02-19 2003-08-28 Pharmacia & Upjohn Company Azabicyclic compounds for the treatment of disease
WO2004052894A1 (en) * 2002-12-06 2004-06-24 Pharmacia & Upjohn Company Llc Crystalline fumarate salts of 1-azabicyclo[2.2.2]oct substituted furo[2,3-c]pyridinyl carboxamide and compositions and preparations thereof
WO2004099202A1 (en) * 2003-05-05 2004-11-18 Pharmacia & Upjohn Company Llc Quinuclidines substituted bentodioxine carboxamides for the treatment of neurodegenerative diseases
US7309699B2 (en) * 2003-12-22 2007-12-18 Abbott Laboratories 3-Quinuclidinyl amino-substituted biaryl derivatives

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464078B2 (en) 2010-09-23 2016-10-11 Abbvie Inc. Monohydrate of azaadamantane derivatives

Also Published As

Publication number Publication date
WO2009102962A2 (en) 2009-08-20
CN101977628A (en) 2011-02-16
PL2254598T3 (en) 2013-12-31
EP2254598B1 (en) 2013-07-10
JP2011511845A (en) 2011-04-14
IL207389A0 (en) 2010-12-30
PT2254598E (en) 2013-10-16
SG188144A1 (en) 2013-03-28
CO6290706A2 (en) 2011-06-20
ES2430622T3 (en) 2013-11-21
RS52941B (en) 2014-02-28
HRP20130749T1 (en) 2013-10-11
AU2009214625A1 (en) 2009-08-20
SI2254598T1 (en) 2013-10-30
RU2010137787A (en) 2012-03-20
EP2254598A2 (en) 2010-12-01
ZA201005999B (en) 2011-05-25
NZ587312A (en) 2011-12-22
KR20100113163A (en) 2010-10-20
ECSP10010471A (en) 2010-10-30
MX2010008875A (en) 2010-08-31
DK2254598T3 (en) 2013-07-29
CA2715268A1 (en) 2009-08-20
BRPI0907570A2 (en) 2019-09-24
CN103143023A (en) 2013-06-12
HK1147954A1 (en) 2011-08-26
RU2481123C2 (en) 2013-05-10
US20110059947A1 (en) 2011-03-10
EP2633868A1 (en) 2013-09-04
CY1114492T1 (en) 2016-10-05

Similar Documents

Publication Publication Date Title
PT2254598E (en) Combination of alpha 7 nicotinic agonists and antipsychotics
IL202510A (en) Agonists of guanylate cyclase, compositions comprising the same and uses thereof
ZA200809941B (en) 2-anilino-4-(heterocyclic)amino-pyrimidines
ZA200706030B (en) GLP-1 agonists, compositions, methods and uses
IL215051A0 (en) Gpr119 agonist compound, compositions comprising the same and uses thereof
ZA200708491B (en) Pyridine-3-carboxamide derivatives as CB1 inverse agonists
IL196355A0 (en) Ep2 agonists
SG171584A1 (en) Nanoparticulate metal boride composition and its use for identification- marking plastic parts
ZA200806140B (en) Improved cellulose articles containing an addictive composition
ZA200809289B (en) Heterocyclic gpcr agonists
IL215050A0 (en) Gpr119 agonist compound, compositions comprising the same and uses thereof
ZA200806392B (en) Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as SIP receptor agonists
IL188329A0 (en) Niacin receptor agonists, compositions containing such compounds and methods of treatment
EP2091957A4 (en) Hydrogen splitting composition
ZA201103044B (en) Conjugates of glp-1 agonists and uses thereof
IL215049A0 (en) Gpr119 agonist compound, compositions comprising the same and uses thereof
IL207372A0 (en) Phenylpyrrole derivatives, compositions comprising the same and uses thereof
IL210498A0 (en) Nitrogen-containing aromatic heterocyclyl compounds, compositions comprising the same and uses thereof
IL212364A0 (en) Neuropeptide-2-receptor (y-2r) agonists and uses thereof
ZA200805203B (en) Lubricant composition with improved solvency
EP1849481A4 (en) Composition for external use
IL184768A0 (en) Controlled release compositions comprising an antipsychotic agent
PL2064185T3 (en) 1h-quinolin-4-one compounds, with affinity for the gaba receptor, processes, uses and compositions
GB0612784D0 (en) Compound, composition and use
IL194689A0 (en) Agent, composition and method

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980110203.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09709577

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 207389

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2715268

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2927/KOLNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009214625

Country of ref document: AU

Ref document number: 587312

Country of ref document: NZ

Ref document number: 2010546920

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/008875

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 12010501839

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: PI 2010003815

Country of ref document: MY

WWE Wipo information: entry into national phase

Ref document number: 2009709577

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009214625

Country of ref document: AU

Date of ref document: 20090213

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20107020088

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 10112124

Country of ref document: CO

WWE Wipo information: entry into national phase

Ref document number: 2010137787

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 12867073

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: P-2013/0387

Country of ref document: RS

ENP Entry into the national phase

Ref document number: PI0907570

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100812